Luigi Aloisio Galvani

Electrical signals from the brain govern much of what goes on in the human body. Pharma and tech giants are spending big money to figure out how to hack these signals, a burgeoning field known as “bioelectronics.” GlaxoSmithKline and Verily Life Sciences, an Alphabet subsidiary, are investing more than $700 million over seven years to create a new company, Galvani Bioelectronics. The firm, 55 percent owned by GSK, will have one lab in Stevenage, U.K., and another in San Francisco...

Read More »